On the public citation graph
Cost-Effectiveness of the Clinical Management of Hepatocellular Carcinoma in Four Asian-Pacific Countries
0 signed · 28 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/hep.27135openalex-extracted
Cost‐effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria
inferredcites →https://doi.org/10.1007/s40273-014-0142-1openalex-extracted
Valuation of EQ-5D-3L Health States in Singapore: Modeling of Time Trade-Off Values for 80 Empirically Observed Health States
inferredcites →https://doi.org/10.1007/s40273-018-0672-zopenalex-extracted
Discounting in Economic Evaluations
inferredcites →https://doi.org/10.1007/s41669-021-00298-zopenalex-extracted
A Systematic Review of Cost-Effectiveness Analyses for Hepatocellular Carcinoma Treatment
inferredcites →https://doi.org/10.1016/j.jhep.2018.03.019openalex-extracted
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
inferredcites →https://doi.org/10.1016/j.jval.2021.10.009openalex-extracted
The Cost-Effectiveness of Selective Internal Radiation Therapies Compared With Sorafenib for Treating Advanced Unresectable Hepatocellular Carcinoma in the United Kingdom
inferredcites →https://doi.org/10.1016/s1499-3872(17)60009-2openalex-extracted
Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma
inferredcites →https://doi.org/10.1037/1082-989x.9.4.403openalex-extracted
Propensity Score Estimation With Boosted Regression for Evaluating Causal Effects in Observational Studies.
inferredcites →https://doi.org/10.1046/j.1365-2036.2002.01307.xopenalex-extracted
Percutaneous ethanol injection vs. resection in patients with small single hepatocellular carcinoma: a retrospective case–control study with cost analysis
inferredcites →https://doi.org/10.1055/s-2007-1007122openalex-extracted
Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification
inferredcites →https://doi.org/10.1080/01621459.1983.10478017openalex-extracted
Smearing Estimate: A Nonparametric Retransformation Method
inferredcites →https://doi.org/10.1080/14737167.2021.1973432openalex-extracted
Cost-benefit analysis of hepatic resection, radiofrequency ablation and liver transplantation in small hepatocellular carcinoma
inferredcites →https://doi.org/10.1080/17474124.2021.1991792openalex-extracted
Current epidemiology in hepatocellular carcinoma
inferredcites →https://doi.org/10.1093/annonc/mdy308openalex-extracted
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
inferredcites →https://doi.org/10.1111/hepr.13892openalex-extracted
Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)
inferredcites →https://doi.org/10.1111/liv.12713openalex-extracted
Treatment of hepatocellular carcinoma: beyond international guidelines
inferredcites →https://doi.org/10.1159/000367759openalex-extracted
National Cancer Centre Singapore Consensus Guidelines for Hepatocellular Carcinoma
inferredcites →https://doi.org/10.1159/000514174openalex-extracted
Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update
inferredcites →https://doi.org/10.1159/000530495openalex-extracted
Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)
inferredcites →https://doi.org/10.1159/000534513openalex-extracted
Real-World Data on the Diagnosis, Treatment, and Management of Hepatocellular Carcinoma in the Asia-Pacific: The INSIGHT Study
inferredcites →https://doi.org/10.1177/23814683211061097openalex-extracted
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations
inferredcites →https://doi.org/10.1185/03007995.2012.691422openalex-extracted
Modelling survival in hepatocellular carcinoma
inferredcites →https://doi.org/10.1186/s12885-018-4308-7openalex-extracted
Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis
inferredcites →https://doi.org/10.1371/journal.pone.0279786openalex-extracted
First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis
inferredcites →https://doi.org/10.21037/hbsn-22-469openalex-extracted
A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights
inferredcites →https://doi.org/10.2165/00019053-200826020-00004openalex-extracted
Modelling Methods for Pharmacoeconomics and Health Technology Assessment
inferredcites →https://doi.org/10.3350/cmh.2022.0294openalex-extracted
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.